Tagrisso-chemo combo expands indication for 1st-line NSCLC treatment
AstraZeneca Korea's Tagrisso (osimertinib) has expanded its indication to include the first-line treatment of EGFR-mutated non-squamous NSCLC. The Ministry of Food and Drug Safety on Monday approved Tagrisso in combination with pemetrexed and platinum- …